Emmanuel Moustakakis, MD
Interventional Cardiology · Flushing, NYNPI 1457514598
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,616 of the $5,472 with a category attached, or 84.4%. 18 manufacturers reported payments, led by Medtronic at 25.5% of the total. Reporting peaked in 2019 at $3,252 and has fallen 89.3% since, to $348 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.
Across 88 payments — averaging $62.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Cardiovascular Systems Inc.$1K
- Biotronik Inc.$678
- Amgen$505
- Abbott$503
- Boston Scientific$415
- plus $938 from 12 others
Across 25 payments — averaging $7296.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$131K
- Abbott$52K
What the payments were for
- Travel & lodging$85616%
- Food & beverage$4,61684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 30 | $1,397 |
| Cardiovascular Systems Inc. | 6 | $1,036 |
| Biotronik Inc. | 7 | $678 |
| Amgen | 15 | $505 |
| Abbott | 4 | $503 |
| Boston Scientific | 5 | $415 |
| Atricure, Inc. | 2 | $221 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| AstraZeneca | 1 | $124 |
| Edwards Lifesciences | 4 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $108 |
| Johnson & Johnson | 4 | $104 |
| Merck | 3 | $53 |
| Boehringer Ingelheim | 1 | $22 |
| Bayer | 1 | $22 |
| Abiomed | 1 | $18 |
| Novartis | 1 | $16 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,472 in reported general payments places this provider in the 40th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 250 | $245,694 |
| EntrestoSacubitril/Valsartan | 100 | $106,502 |
| Repatha SureclickEvolocumab | 64 | $80,079 |
| XareltoRivaroxaban | 50 | $59,352 |
| Praluent PenAlirocumab | 43 | $40,700 |
| BrilintaTicagrelor | 40 | $35,044 |
| FarxigaDapagliflozin Propanediol | 32 | $28,962 |
| JardianceEmpagliflozin | 12 | $21,108 |
| Repatha SyringeEvolocumab | 13 | $11,340 |
| Metoprolol Succinate | 451 | $6,909 |
| Ranolazine ErRanolazine | 35 | $6,693 |
| Atorvastatin Calcium | 499 | $5,577 |
| Rosuvastatin Calcium | 265 | $5,252 |
| Olmesartan Medoxomil | 147 | $3,219 |
| Labetalol Hcl | 89 | $3,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $245,694250 claims |
| NovartisEntresto | $16 | $106,502100 claims |
| AstraZenecaBrilinta, Farxiga | $124 | $64,00672 claims |
| Johnson & JohnsonXarelto | $104 | $59,35250 claims |
| Boehringer IngelheimJardiance | $22 | $21,10812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Flushing
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.